Evidence map›Paper›PMID 24596469›Full record

ArticleClinicoEconomics and outcomes research : CEOR2014

Duloxetine treatment adherence across mental health and chronic pain conditions.

Stephen L Able, Zhanglin Cui, Wei Shen

Registry-linked trialAbstract read
In one paragraph

Article in ClinicoEconomics and outcomes research : CEOR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07455409 (A Single-Arm Pilot Study of the Feasibility and Efficacy of Electro-Acupuncture in Subjects With Chemotherapy-Induced Peripheral Neuropathy), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07455409 nacompletednot on this mapstarted 2019, after this paper: background citation

A Single-Arm Pilot Study of the Feasibility and Efficacy of Electro-Acupuncture in Subjects With Chemotherapy-Induced Peripheral Neuropathy

TypeinterventionalSponsorThe Methodist Hospital Research InstituteRan2019 to 2023Enrolled20ConditionsChemotherapy-induced Peripheral NeuropathyArmsElectro-acupuncture
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Review
  3. Determination of Patient Adherence for Duloxetine in Urine.Journal of analytical toxicology · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Stephen L AbleGlobal Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA.
Zhanglin CuiGlobal Statistical Sciences, Eli Lilly and Company, Indianapolis, IN, USA.
Wei ShenGlobal Statistical Sciences, Eli Lilly and Company, Indianapolis, IN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study applied a uniform methodology for measuring and comparing duloxetine adherence in the treatment of multiple chronic medical conditions. MATERIALS AND

methodsStudy patients 18-64 years of age initiating duloxetine therapy during 2008 were identified from a large managed care database. The study was restricted to patients with continuous health plan eligibility for 12 months pre- and post-duloxetine initiation. Study patients had ≥1 medical claim with an inpatient or outpatient diagnosis of one (and only one) of the following conditions: major depressive disorder (MDD); generalized anxiety disorder (GAD); fibromyalgia, diabetic peripheral neuropathic pain; or chronic musculoskeletal pain, as established in studies in patients with osteoarthritis and chronic lower back pain (CLBP). Patients initiating duloxetine who had two or more of the six studied conditions were not included in this study, thereby avoiding the need to differentiate between primary and secondary diagnoses from the claims records. Adherence rate was defined as the percentage of patients with a 365-day medication possession ratio ≥0.8.

resultsA total of 20,490 patients initiated duloxetine treatment during 2008 with a diagnosis of one of the studied conditions during the study period. The adherence rate in our sample was 34.6% and was highest among patients with MDD (37.3%) and lowest for patients with CLBP (29.9%). In general, adherence among patients with MDD and GAD was greater than among those with a chronic pain condition.

conclusionAdherence among newly initiated duloxetine patients varied modestly across the medical conditions for which it was used. After adjusting for potential confounders, differences between the mental conditions (MDD and GAD) and the chronic pain conditions (CLBP, osteoarthritis, and diabetic peripheral neuropathic pain) were statistically significant. These results may be useful in the determination of expectations of adherence, and how it may differ for each of the conditions studied.

Indexed as

adherencechronic lower back paindiabetic peripheral neuropathic painduloxetinegeneralized anxiety disordermajor depressive disorder

Identifiers

PMID24596469
PMCPMC3930481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.